MetaCap

Burning Rock Biotech Limited ADR (BNR)

NASDAQ: BNRHealth CareMedical SpecialitiesUSD

13.24-0.08 (-0.60%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BNR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$139.63M
EPS (TTM)
-$0.80
52-week range
6.79 – 41.72
Day range
11.10 – 13.46
Volume / Avg
27.87K / 36.51K
Beta
—

52-week range

$6.79$41.72

BNR stock today

Shares of Burning Rock Biotech (BNR) finished lower on Nov 20 at $13.24, a drop of 0.60% or $0.08 per share, versus the S&P 500's 3.70% decline. At this level, BNR sits near the bottom of its 52-week range of $6.79 to $41.72: 68.3% below the high, set on Jan 22, 2026 and 95.0% above the low. BNR is down 34.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 7.1%.

Burning Rock Biotech has posted a net loss over the last twelve months (EPS of -$0.80), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Burning Rock Biotech

Company profile

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Industry
Medical Specialities
CEO
Mr. Yusheng Han
Headquarters
Guangzhou
Employees
667
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Burning Rock Biotech generated $77.2 million in revenue, up 9.2% from fiscal 2024. Burning Rock Biotech reported a net loss of $7.9 million, compared with a loss of $47.5 million a year earlier. Gross margin was 74.7% (up from 70.3%) and operating margin -10.2%.

Burning Rock Biotech annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$77.16M$70.67M$75.70M$81.66M$79.69M
Growth+9.18%-6.64%-7.31%+2.47%+20.96%
Net income$-7.92M$-47.49M$-92.07M$-140.81M$-125.02M
EPS (diluted)————$0.00

Earnings

Earnings history
Last reported (Sep/2026)
Nov 19, 2026
EPS actual vs est.
$-0.26 vs —

BNR news

All BNR news

Burning Rock Biotech peers

Health Care sector
BNR peer companies
CompanyPrice% ChgMarket capCompare
TLSITriSalus Life Sciences Inc.2.32+6.67%$143.14Mvs BNR
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs BNR
XGNExagen Inc.3.61-5.00%$92.10Mvs BNR
BDSXBiodesix Inc.7.56-8.92%$83.83Mvs BNR
SERASera Prognostics Inc. Class A1.81-4.23%$71.98Mvs BNR
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs BNR
AMSAmerican Shared Hospital Services1.00-4.76%$6.67Mvs BNR
ACONAclarion Inc.1.22-13.92%$3.52Mvs BNR

Indexes, lists and sector

Burning Rock Biotech stock FAQ

What is Burning Rock Biotech's stock price today?

BNR last traded at $13.24 as of Nov 20, 4:00 PM EST, down 0.60% on the day. Prices are delayed at least 15 minutes.

Does Burning Rock Biotech pay a dividend?

No. Burning Rock Biotech does not currently pay a regular cash dividend.

Who is Burning Rock Biotech's CEO?

Mr. Yusheng Han is the chief executive officer of Burning Rock Biotech Limited ADR, which has about 667 employees.

Has BNR ever split its stock?

Yes. The most recent BNR stock split was a 1-for-10 split on May 15, 2024.

What is the BNR 52-week high?

The 52-week high for BNR is $41.72 and the 52-week low is $6.79. The stock is currently 68.3% below its high.

Compare BNR